

Having trouble finding Clarithromycin at your pharmacy? Learn why this macrolide antibiotic can be hard to find in 2026 and what you can do about it.
You just left the doctor's office with a prescription for Clarithromycin — maybe for a sinus infection, bronchitis, or an H. pylori stomach ulcer regimen. You head to the pharmacy, only to hear the dreaded words: "We don't have it in stock right now."
If that's happened to you, you're not alone. While Clarithromycin isn't experiencing a nationwide shortage on the scale of some other medications, many patients in 2026 are running into availability problems at their local pharmacy. Let's break down what's going on and what you can do about it.
Clarithromycin is a macrolide antibiotic sold under the brand name Biaxin. It's used to treat a wide range of bacterial infections, including:
It comes as an immediate-release tablet (250 mg and 500 mg), an extended-release tablet (Biaxin XL, 500 mg), and an oral suspension for children. For a deeper look at the medication, check out our guide on what Clarithromycin is, its uses, and dosage.
The brand-name version of Clarithromycin (Biaxin) has been largely discontinued, and nearly all supply comes from generic manufacturers like Teva, Sandoz, Sun Pharma, and Aurobindo. When any of these companies faces production delays — due to equipment issues, raw material shortages, or FDA inspection findings — it can create a ripple effect that leaves pharmacy shelves empty in certain regions.
Clarithromycin is primarily prescribed for respiratory infections. During cold and flu season (roughly October through March), demand can surge dramatically. When prescriptions spike faster than manufacturers can ship, pharmacies may temporarily run out. This is especially true in communities hit hard by respiratory illness outbreaks.
A handful of generic manufacturers produce the majority of the Clarithromycin supply in the United States. Most active pharmaceutical ingredients (APIs) are sourced from overseas facilities. If even one major supplier hits a snag, there may not be enough backup capacity to fill the gap quickly. This concentration of supply is a systemic problem affecting many generic antibiotics, not just Clarithromycin.
Many chain pharmacies use automated inventory systems that order medications based on recent dispensing patterns. If a pharmacy hasn't filled many Clarithromycin prescriptions recently, it may not keep large quantities on hand. This means even without a true shortage, your local pharmacy might simply not have it when you need it.
If your pharmacy doesn't have Clarithromycin in stock, don't panic. Here are practical steps you can take:
Cost can also be a barrier. Without insurance, the cash price for a typical 14-day course of Clarithromycin 500 mg can range from about $14 to $148, depending on the pharmacy and whether you use a discount coupon. With a coupon from GoodRx or SingleCare, most patients pay between $16 and $25. The extended-release version tends to cost more — around $52 to $243 for 14 tablets at retail. For more money-saving tips, see our guide on how to save money on Clarithromycin.
Clarithromycin is a widely used and generally available antibiotic, but supply hiccups can and do happen — especially during respiratory illness season. The good news is that with a little persistence and the right tools, most patients can find it in stock nearby. Start with Medfinder to check local availability, and don't hesitate to talk to your doctor about alternatives if you're stuck.
For the latest on Clarithromycin availability, see our 2026 shortage update.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.